Management of Patients with Type 1 von Willebrand Disease Undergoing Invasive Procedures

Pre-Procedure Assessment

• Type 1 von Willebrand disease accounts for approximately 75% of symptomatic VWD cases and is characterized by partial quantitative deficiency of von Willebrand factor (VWF) 1
• Patients with VWD are at increased risk of bleeding following invasive procedures, including colonoscopy with biopsies 1
• The presence of mild thrombocytopenia represents an additional, though modest, bleeding risk factor 2

Management Recommendations

• The American College of Cardiology notes that colonoscopy with biopsy is generally considered a low-risk procedure for bleeding, with rates of post-polypectomy bleeding ranging from 0.4% to 3.4% 3
• However, the presence of VWD increases this baseline risk, necessitating prophylactic management 1
• The procedure should be performed on a scheduled list rather than emergently, allowing for proper preparation and prophylactic treatment 4

Laboratory Assessment

• Prior to the procedure, obtain a complete blood count to confirm current platelet level, VWF antigen level, and factor VIII activity level to guide appropriate dosing of desmopressin 2

Special Considerations

• Advanced age is an independent risk factor for post-polypectomy bleeding, warranting extra caution 3
• If multiple or large biopsies are anticipated, consider using cold biopsy techniques when possible, as they are associated with less bleeding than hot biopsy techniques 3

Post-Procedure Monitoring

• Monitor the patient for at least 2-4 hours post-procedure for signs of bleeding 4
• Instruct the patient to report any signs of delayed bleeding, which can occur up to 21 days after the procedure 3
• Consider a follow-up assessment of hemoglobin level if multiple biopsies were performed 4

Management of Colonoscopy with Potential Biopsies in Patients with Bleeding Disorders

Pre-Procedure Assessment and Planning

• A platelet count of >50,000/μL is generally considered safe for invasive procedures, including colonoscopy with biopsies, according to the American Society of Clinical Oncology 5, 6

Laboratory Assessment

• A platelet count >50,000/μL is considered safe for invasive procedures, including colonoscopy with biopsies, as recommended by the American Society of Clinical Oncology 5, 6
• Assessing coagulation parameters is essential to evaluate potential bleeding risk, as suggested by the World Journal of Emergency Surgery 7

Treatment Recommendations

• The International Society on Thrombosis and Haemostasis recommends administering VWF concentrate before the procedure to achieve VWF activity levels of at least 50 IU/dL 8

Procedure Considerations

• Ensuring a post-treatment VWF level and platelet count are obtained to confirm that the desired levels have been reached before proceeding is crucial, as recommended by the American Society of Clinical Oncology 5
• Having additional VWF concentrate readily available in case of intraoperative or postoperative bleeding is essential, as suggested by the American Society of Clinical Oncology 5

Post-Procedure Monitoring

• Maintaining VWF activity levels >50 IU/dL until adequate hemostasis is achieved is recommended by the International Society on Thrombosis and Haemostasis 8

Colonoscopy Safety in Thrombocytopenia

Risk Assessment Based on Platelet Count

• The American Society of Clinical Oncology recommends that colonoscopy can be safely performed in patients with platelet counts above 50,000/μL without prophylactic platelet transfusion 9
• For patients with platelet counts between 20,000-50,000/μL, the decision should be based on procedure urgency and bleeding risk, with diagnostic colonoscopy without biopsies potentially performed at counts >20,000/μL, and therapeutic interventions requiring counts >50,000/μL 9, 10
• Patients with platelet counts <20,000/μL should receive platelet transfusion before any colonoscopy procedure, as recommended by the American Society of Clinical Oncology 11

Procedure-Specific Considerations

• The American College of Cardiology considers diagnostic colonoscopy without biopsies a low-risk procedure, with a bleeding risk of 0.4% to 3.4% for colonoscopy with polypectomy, which increases with polyp size ≥10 mm 12

Pre-Procedure Management

• The American Society of Clinical Oncology recommends that for patients requiring platelet transfusion, it is critical to obtain a post-transfusion platelet count to confirm that the desired level has been reached, and that platelet transfusions should be closely coordinated with the timing of the colonoscopy 9, 11

Special Considerations

• The American College of Cardiology identifies risk factors for increased bleeding during colonoscopy, including advanced age, hypertension, diabetes, coronary artery disease, and chronic obstructive pulmonary disease, as well as polyp size ≥10 mm and location in the proximal colon 12
• For patients with cirrhosis and thrombocytopenia, the American Gastroenterological Association recommends considering TPO receptor agonists (avatrombopag, lusutrombopag) to raise platelet counts before procedures, which have been shown to significantly reduce the need for platelet transfusions compared to placebo 10, 13

Technical Considerations During Procedure

• The American Society of Clinical Oncology recommends the use of endoscopic hemostasis techniques (endoclips, epinephrine injection), which are effective even in thrombocytopenic patients 9

Post-Procedure Monitoring

• The American College of Cardiology recommends monitoring for signs of bleeding for at least 2-4 hours post-procedure and instructing patients to report any signs of delayed bleeding, which can occur up to 21 days after polypectomy, classically presenting as passage of large-volume bloody bowel movements 12

Safe Platelet Count Threshold for Colonoscopy

Platelet Count Thresholds by Procedure Type

• The American Society of Clinical Oncology guidelines suggest that a platelet count of 40,000-50,000/μL is sufficient to perform major invasive procedures safely 14
• A platelet count of at least 50,000/μL is generally considered safe for performing colonoscopy with potential biopsies 14

Risk Stratification

• Patients with concurrent coagulopathy may require higher platelet thresholds 15
• Patients with a history of bleeding disorders may require higher platelet thresholds 14

Procedure-Specific Risk Factors

• Proximal colon interventions increase bleeding risk 15
• Polypectomy (especially polyps ≥10mm) increases bleeding risk 16

Evidence from Clinical Studies

• Patients with cirrhosis undergoing colonoscopy with polypectomy showed that bleeding risk was higher when platelet counts were lower, with increased risk when counts were <60,000/μL 17

Management Recommendations

• Obtain complete blood count to confirm current platelet level 15
• Consider prophylactic platelet transfusion for counts <50,000/μL when biopsies are anticipated 17
• Have platelet transfusions available on short notice in case of intraoperative bleeding 14
• Avoid loop formation and gentle endoscope progression to minimize trauma 16

Special Considerations

• In patients with cirrhosis, decompensated disease is an independent risk factor for post-procedural bleeding, regardless of platelet count 17
• Patients receiving chemotherapy may have platelet dysfunction even with adequate counts, warranting extra caution 18